No Detail Found!

Dexmedetomidine As An Antiepileptic in Super Refractory Status Epilepticus.

Author(s)
Bikram Kumar Gupta 1Department of Anesthesiology, Banaras Hindu University, [BHU], Varanasi, U.P. India
Arun Raj Pandey Department of Anesthesiology, Critical Care and Pain, Homi Bhaba Cancer Hospital,TMC,Varanasi, India
Shardendu Singh Department of Anesthesiology, Critical Care and Pain, Homi Bhaba Cancer Hospital,TMC,Varanasi, India
Madhup Kumar Singh Department of Anesthesiology, Critical Care and Pain, Homi Bhaba Cancer Hospital,TMC,Varanasi, India
Abstract
Refractory and super-refractory status epilepticus (SRSE) is a life-threatening neurological emergency, associated with very high morbidity and mortality. Treatment should be aimed to stop seizure and to avoid cerebral damage and morbidity related to it. The term SRSE is reserved for the patients who continue to have seizures despite the use of general anesthetic agents, or for whom seizures recur when therapy is tapered or withdrawn. A variety of treatment modalities are present, almost entirely based upon open observational studies or case reports. Therapy includes anesthesia, antiepileptic drug therapy, hypothermia, ketogenic diet, other medical, immunological, and physical therapies. In our case the patient’s seizure subsided after starting dexmedetomidine infusion while other antiepileptics had been completely stopped except valproic acid.
Publication Details
Page(s) 75-77
DOI DOI not available
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 23, Issue: 1, Year: 2019

Request the full text from PASTIC

Keywords
Super refractory status epilepticus, Dexmedetomidine, Neurocritical care
0

Citations

0

Downloads

83

Views